List of Valcyte drug patents
Valcyte is owned by Hoffmann La Roche.
Valcyte contains Valganciclovir Hydrochloride.
Valcyte has a total of 2 drug patents out of which 0 drug patents have expired.
Valcyte was authorised for market use on 28 August, 2009.
Valcyte is available in for solution;oral dosage forms.
The generics of Valcyte are possible to be released after 11 December, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642911 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(4 years from now) | |
| US8889109 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(4 years from now) | |
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2009
Treatment: NA
Dosage: FOR SOLUTION;ORAL
VALCYTE family patents
8
United States
2
European Union
1
Portugal
1
Malaysia
1
Russia
1
Spain
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
Norway
1
Mexico
1
Argentina
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
South Africa
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
Ukraine
1
Israel
1
Poland
1
Chile
1
Australia
1
RS
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic